Phase II multicenter single arm study to evaluate the efficacy and safety of Ibrutinim in combination to Rituximab-CHOP followed by Ibrutinib maintanance in untreated patients with Activated-B-Cell (ABC) - DLBCL at intermediate-high and high risk (IP≥2). (FIL_RI-CHOP)